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Background: Given the heterogeneous nature of Crohn’s disease
(CD), our aim was to apply the Montreal Classiﬁcation to a large
cohort of Portuguese patients with CD in order to identify potential
predictive regarding the need for medical and/or surgical treatment.
Methods: A cross-sectional study was used based on data from an
on-line registry of patients with CD.
Results: Of the 1692 patients with 5 or more years of disease, 747
(44%) were male and 945 (56%) female. On multivariate analysis
the A2 group was an independent risk factor of the need for steroids
(odds ratio [OR] 1.6, 95% conﬁdence interval [CI] 1.1–2.3) and the
A1 and A2 groups for immunosuppressants (OR 2.2; CI 1.2–3.8; OR
1.4; CI 1.0–2.0, respectively). An L3L34 and L4 location were risk
factors for immunosuppression (OR 1.9; CI 1.5–2.4), whereas an L1
location was signiﬁcantly associated with the need for abdominal
surgery (P  0.001). After 20 years of disease, less than 10% of
patients persisted without steroids, immunosuppression, or surgery.
The Montreal Classiﬁcation allowed us to identify different groups
of disease severity: A1 were more immunosuppressed without sur-
gery, most of A2 patients were submitted to surgery, and 52% of
L1L14 patients were operated without immunosuppressants.
Conclusions: Stratifying patients according to the Montreal Clas-
siﬁcation may prove useful in identifying different phenotypes with
different therapies and severity. Most of our patients have severe
disease.
(Inﬂamm Bowel Dis 2009;15:1343–1350)
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C rohn’s disease (CD) is a chronic inﬂammatory diseaseassociated with signiﬁcant morbidity due to a frequent
need for intestinal resections and hospitalizations. Accurate
classiﬁcation of CD would be most helpful in this respect to
allow an early assessment of disease prognosis, thereby iden-
tifying and selecting patients for the most appropriate therapy
according to disease subtype. The Montreal1 revision of the
Vienna Classiﬁcation, to our knowledge, was never validated
in a large population cohort.
Furthermore, geographic variations in CD incidence
and prevalence have long been reported, with Scandinavian
countries exhibiting a higher incidence, as well as a more
aggressive behavior as compared to patients from southern
Europe.2 However, this assumption might be difﬁcult to sub-
stantiate because, so far, very few population-based studies
from southern Europe have been published. Also, most stud-
ies reporting on the natural history of CD utilized referral
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centers, which may create a “referral center” bias, that is,
patients referred to quaternary medical centers may have the
most severe phenotypes, most likely to undergo surgery and
multiple medications, and may well not be a representative
sample.
The purpose of the present study was to apply the
Montreal Classiﬁcation in a large cohort of Portuguese pa-
tients with CD from several centers across the country in
order to minimize “referral bias” and then search for predic-
tive factors that would enable us to identify patients requiring
steroid treatment, immunosuppression, and/or abdominal sur-
gery. The Montreal Classiﬁcation was used to allow a uni-
form and standardized classiﬁcation of the cohort, thereby
making possible for us to understand the clinical activity of
this group of patients in a southern European country.
PATIENTS AND METHODS
Patient Inclusion
From September 2004 until December 2006, all medi-
cal doctors in Portugal (gastroenterologists, pediatricians,
surgeons, and general practioners) were invited to include
patients with IBD in a national database registry. Our national
database was approved by national authorities and was im-
plemented by the Portuguese group of studies for IBD (http://
www.gedi.med.up.pt/). It is a cross-sectional study that in-
cludes 77 Portuguese MDs coming from 33 medical centers,
distributed all over Portugal, from north to south, including
the islands of Madeira and Azores. Patient registration was
carried out through a Web-based system with password and
user name validated by a scientiﬁc committee. The patients
came from quaternary and tertiary referral hospitals (48.6%)
and regional hospitals plus private practice (50.7%). A small
percentage (0.5%) was included by pediatricians working in
referral pediatric centers. These ﬁgures represent about 50%
of the calculated number of Portuguese patients with IBD. All
deﬁnitions of the material form were online and all partici-
pants had at least 3 meetings per year to discuss the inclusion
criteria. All patients included in the present study had to
fulﬁll the strict international diagnostic criteria for IBD.3 In
addition, all patients were required to have at least 2 criteria
from the Copenhagen Diagnostic Criteria of CD.3
Data Collection
Information on date of onset of symptoms and diagno-
sis, type of clinical onset, extent of disease, familial occur-
rence of IBD, presence of extraintestinal manifestations, type
of colonic involvement, presence of rectal involvement, type
of anal lesion, previous history of abdominal abscesses and/or
ﬁstulas, clinical course, response to steroids, immunosuppres-
sion and/or biologic treatment, as well as previous abdominal
or anal surgery was collected. Abdominal surgery was con-
sidered as such when patients submitted to surgery for intes-
tinal resection, abscess drainage, strituroplasty, or another
procedure such as appendectomy or acute abdomen without
intestinal resection (i.e., diagnosis of CD without resection).
The Montreal Classiﬁcation1 was used. In this classiﬁcation,
L4 is a modiﬁer that can be added to L1–L3 when concom-
itant upper gastrointestinal (GI) disease is present. Behavior
was deﬁned as B1 nonstricturing, nonpenetrating, B2 stric-
turing, B3 penetrating, and p is added to B1–B3 when con-
comitant perianal disease is present. Patients were deﬁned as
steroid-dependent if it was not possible to decrease the pred-
nisolone dose below 10 mg/day or if they required 2 or more
steroid treatments (1 mg/kg) within a period of 6 months.
Steroid resistance was deﬁned as an incapability of inducing
remission with steroids at a dose of 1 mg/kg. Patients who
have had treatment with azathioprine, 6-MP, cyclosporine, or
methotrexate were included in the immunosuppression group.
Disease Severity
Patients were classiﬁed in 6 disease severity categories,
a modiﬁcation of the Silverstein et al4 classiﬁcation. Score 1
was reserved for mild disease (without steroids, immunosup-
pressants, biologic treatment, or surgery at any given year of
disease); score 2 for moderate disease (patients treated with
corticosteroids requiring a dose of prednisolone above 10
mg/day or 2 or more steroid treatments within a period of 6
months); score 3 for severe disease (patients treated with
immunosuppressants without biologic treatment or surgery);
score 4 for severe refractory disease (patients treated with
immunosuppressants and biologic treatment without sur-
gery); score 5 for surgically treated disease (patients without
use of immunosuppressants or biologic treatment); and ﬁ-
nally, score 6 for severe refractory disease who came to need
surgery and also immunosuppressants and biologic treatment.
Statistics
The Kolmogorov–Smirnov test was used to test for
normality. When testing a hypothesis about continuous vari-
ables, parametric tests (Student’s t-test and 1-factor analysis
of variance, ANOVA) and nonparametric tests (Mann–Whit-
ney and Kruskal–Wallis tests) were used as appropriate,
taking into account normality assumptions and the number of
groups compared. When testing a hypothesis about categor-
ical variables a chi-square test and Fisher’s exact test were
used, as appropriate. In order to have a more thorough un-
derstanding of the factors associated with the use of steroid
therapy, immunosuppression and abdominal surgery univar-
iate and multivariate logistic regression modeling was used.
In the multivariate logistic regression models the dependent
variables were steroid therapy, immunosuppression, and ab-
dominal surgery. Model goodness-of-ﬁt was assessed using
the Hosmer–Lemeshow statistic and discriminative power
was evaluated by receiver-operator curve (ROC) curve anal-
ysis. The inﬂuence of outlier data values on model ﬁt was
Magro et al Inﬂamm Bowel Dis ● Volume 15, Number 9, September 2009
1344
estimated using leverage statistics, and collinearity was as-
sessed by evaluation of coefﬁcients correlation matrix. Be-
cause of the multiple hypothesis tests performed and pre-
sented in this study, the inﬂation of type I error is a risk.
Whenever statistical hypothesis testing is used and in order to
take into account a correction for the multiple comparisons
presented, using the Bonferroni method, the signiﬁcance level
should be adequately corrected to   0.002 instead of the
traditional   0.05 level. Statistical analysis was performed
using the software Statistical Package for the Social Sciences
v. 15.0 for Windows (SPSS, Chicago, IL).
RESULTS
Analysis of Montreal Categories
Of the 2854 patients with CD in our database, 1245
(44%) were male and 1609 (56%) female, with a mean age at
diagnosis of 32  14 years and a median time after diagnosis
of 6 years (percentile 25, 2 and percentile 75, 11). Only
patients with 5 or more years of disease were included in this
analysis because it is a necessary timepoint before behavior
might be classiﬁed. This approach seems to be imperative
when results of different centers are compared. Behavior
progression and clinical severity at different intervals of
disease duration are shown in Figure 1. Sixty percent of
patients in the ﬁrst year of disease were categorized as B1;
moreover, this percentage decreases with disease progression
and only 28% of those with 15–19 years of disease had no
stenosing or penetrating event (B1). By contrast, the B3
group increases in those with longer disease duration, achiev-
ing 42% in the longest affected group. Considering disease
severity, we observed that during the ﬁrst 4 years of disease
the median severity was 3 (interquartile range 1–5), increas-
ing to 4 (3–5) in those with 10–14 years of disease, and to 5
(3–5) in patients with 15–19 years of disease duration.
Table 1 shows characteristics of our study group ac-
cording to age of diagnosis. Of the 1692 patients, 747 (44%)
were male and 945 (56%) female. Mean age at diagnosis was
31  13 years. Median time after diagnosis was 10 years
(percentile 25, 7 and percentile 75, 16). With regard to age at
diagnosis, 8% were classiﬁed as A1 (below 16 years), 73% as
A2 (below 40 years), and 19% as A3 (above 40 years).
Median time of follow-up after diagnosis was 10 years (per-
centile 25%, 7; percentile 75%, 16). A family history of IBD
was present in 8% of the patients.
Table 2 shows classiﬁcation of patients according to the
Montreal Classiﬁcation. Appropriate allocation of patients to
different categories of disease location, age of onset, and
behavior was possible in 1413 patients: 34% were classiﬁed
as L1 (ileal), 15% as L2 (colonic), 45% as L3 (ileocolonic),
and 1% as L4 (upper GI disease). B1 (nonstricturing, non-
penetrating) phenotype was found in 38% of patients; B2
(structuring) in 26% and B3 (penetrating) in 36%. Colonic
FIGURE1. Behavior categories according to theMontreal Clas-
siﬁcation and clinical activity in different intervals of disease
duration. Relative frequency (percentage) for each disease be-
havior category: Montreal Classiﬁcation (left axis) and disease
severity index (right axis) classiﬁed in 6 disease severity catego-
ries according to the modiﬁed Silverstein et al4 classiﬁcation for
each of the disease duration groups: 1 year (n  274); 1–4
years (n 761); 5–9 years (n 673); 10–14 years (n 354); and
15–19 years (n 191).
TABLE 1. Baseline Population Characteristics
Age at Diagnosis
Pa 16 years N (%) 17–40 years N (%) 40 years N (%)  N (%)
Gender
Male 63 (45) 541 (44) 143 (45) 747 (44) 0.107
Female 77 (55) 691 (56) 177 (55) 945 (56)
Age (mean  SD) 13 2 27  6 52 9 31  13
Years of diseaseb 10 (7–16) 10 (7–16) 9 (6–14) 10 (7–16) 0.003
Family history of IBD 8 (7) 77 (9) 14 (7) 99 (8) 0.546
aContinuous variables were compared by Kruskal-Wallis (variables where normal distribution could not be assumed) and by 1 factor analysis of variance
(variables where normal distribution could be assumed) and for categorical variables the Pearson chi-square test was used.
bMedian (percentile 25 –percentile 75) after diagnosis.
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involvement was total in 23% patients, proximal in 30%,
segmental in 32%, and left colonic involvement in 15%.
Analysis of Location, Behavior, and Treatment
According to Age of Onset of CD
A signiﬁcant association between the age at diagnosis
and disease location was found, with the youngest population
(A1) exhibiting predominantly L3 involvement, whereas the
oldest patients (A3) had mainly an L2 location (P  0.001).
The A1 group of patients were more often steroid-dependent
(36%, P  0.030) and were more often taking immunosup-
pressants (62%, P  0.001) and biologic agents (22%, P
 0.001) (Table 3). By contrast, we observed that the A3
group (40 years at diagnosis) had a lower incidence of
abdominal ﬁstulas and both steroids and immunosuppressants
were less often prescribed (Table 3).
Severity
The population was stratiﬁed by different years of
disease duration. In all, 1704 patients had at least 5 years of
disease, 919 patients 10 or more years, 497 at least 15 years,
262 20 or more years of disease, and 136 had disease for at
least 25 years. It was observed that only a minority of patients
(10%) did not receive steroids, immunosuppressants, or
were submitted to abdominal surgery. Twenty-seven percent
of patients became steroid-dependent and 49% of them re-
quired immunosuppressants, with or without biologic treat-
ment. Of note, the majority of patients required surgery at
some point—at 5 years of diagnosis the ﬁrst surgery rate was
22% rising to 38.5%, 52%, 67%, and 66%, at 5–9, 10–14,
15–19, 20–24, and more than 25 years after diagnosis, re-
spectively. Table 4 shows the severity of disease in 6 differ-
ent categories according to the Silverstein et al4 modiﬁed
classiﬁcation. Thus, considering age of onset it was observed
that 20% patients in the A3 group were assessed as mild
disease and only 7% were stratiﬁed in the highest severe
TABLE 2. Allocation of Patients to All 126 Subgroups of the Montreal Classiﬁcation
A1 A2 A3
B1 B2 B3 B1p B2p B3p B1 B2 B3 B1p B2p B3p B1 B2 B3 B1p B2p B3p 
L1 0.8 0.5 0.4 0 0.3 0.1 6.4 9.1 6.7 0.2 0.6 1.7 2.4 2.3 1.8 0.1 0.1 0.4 33.8
L2 0.8 0.1 0.2 0 0.1 0.3 6.9 0.5 1.6 0.6 0.1 0.8 1.8 0.4 0.6 0.4 0 0.1 15.1
L3 1.4 0.8 1.1 0 0.1 0.6 9.8 7.5 10.3 0.7 0.6 4.3 2.8 1.6 2.0 0.1 0.1 0.7 44.7
L4 0 0 0 0 0 0 0.3 0.5 0.2 0 0 0 0.1 0.1 0 0 0 0 1.2
L14 0.2 0 0.1 0 0 0 0.8 0.6 0.8 0 0.1 0 0.3 0.3 0.2 0 0 0 3.3
L24 0 0.1 0.1 0 0 0 0.4 0.1 0.5 0 0 0.1 0.1 0.1 0.1 0 0 0 1.5
L34 0 0 0 0 0 0 0.1 0.1 0 0 0 0 0 0 0.1 0 0 0 0.4
 3.3 1.5 1.9 0 0.5 1 24.7 18.3 20 1.6 1.3 6.9 7.6 4.7 4.8 0.6 0.2 1.2 100
Percentage of the total population (n1413) is shown.
TABLE 3. Contingency Table for Age at Diagnosis, Type of
Penetrating Events, Medical and Surgical Treatment
A1
N (%)
A2
N (%)
A3
N (%) Pa
Location
L1L14 66 (32) 733 (36) 226 (38)
L2L24 31 (15) 408 (20) 161 (27) 0.001
L3L34 107 (52) 847 (42) 208 (35)
L4 2 (1) 22 (1) 7 (1)
Upper GI involvement
7(5) 72 (6) 22 (7) 0.693
Behavior
B1B1p 86 (48) 788 (45) 273 (52)
B2B2p 45 (25) 444 (25) 123 (23) 0.047
B3B3p 49 (27) 527 (30) 128 (24)
EIM 61 (44) 429 (35) 110 (35) 0.07
Abdominal penetrating events
Abscesses 24 (17) 176 (15) 38 (12) 0.298
Fistulas 21 (15) 231 (19) 39 (12) 0.018
Anal penetrating events
Fissures 17 (12) 93 (8) 15 (5) 0.018
Abscesses 22 (16) 165 (13) 36 (11) 0.391
Fistulas 34 (23) 271 (22) 62 (19) 0.442
Patients treated
with steroids 119 (88) 965 (82) 214 (72) 0.001
Steroid dependent 42 (36) 266 (28) 47 (22) 0.030
Steroid resistant 9 (8) 58 (6) 9 (4) 0.434
Immunosuppression 85 (62) 621 (51) 121 (38) 0.001
Biologic treatment 30 (22) 222 (18) 41 (13) 0.020
Abdominal surgery 64 (46) 609 (50) 141 (44) 0.215
Anal surgery 23 (17) 231 (19) 44 (14) 0.098
EIM, extraintestinal manifestations.
aPearson chi-square test.
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score. In contrast, the majority of A1 patients were treated
with immunosuppressants without need of surgery and most
of the A2 patients submitted to surgery (49%). When the
patients were categorized by location it was possible to iden-
tify different groups of activity. It is very interesting that 52%
of L1L14 were operated on without immunosuppressants or
biologic treatment. Regarding behavior classiﬁcation, in the
B1 group 30% of patients were classiﬁed as having mild
disease, and in contrast 77% of penetrating patients required
surgery.
Univariate and Multivariate Analysis of Factors
Associated with Steroid Therapy,
Immunosuppression, and Abdominal Surgery
Table 5 shows the variables that were associated with
the use of steroids, immunosuppressants, and/or surgery on
uni- and multivariate analysis. Of interest, early age of dis-
ease onset did not represent a risk factor for steroid depen-
dency or abdominal surgery; however, the presence of ex-
traintestinal manifestations (EIMs) was associated with
increased risk of steroid dependence. With respect to immu-
nosuppressants, we observed that besides the A1 and A2
groups, other risk factors were L3L34 and L4 location,
B2B2p and B3B3p groups, and the presence of perianal
disease, EIM, as well as the previous use of steroids, namely,
steroid dependency (odds ratio [OR] 10.3; 95% conﬁdence
interval [CI] 7.1–15.0) or steroid resistance (OR 6.7; CI
2.8–16.0). With regard to surgery, multivariate analysis
showed that risk factors were L1L14 location, B2B2p and
B3B3p behaviors, the presence of abdominal abscesses or
ﬁstulas, and steroid resistance.
DISCUSSION
Based on mesalamine consumption in the year 2005
and considering a daily drug intake-deﬁned dose (DDD) of 2
g/day, the prevalence of IBD in Portugal was estimated to be
118 per 100,000 inhabitants, that is, 12,508 estimated Portu-
guese patients with IBD. The same study estimated a preva-
lence of CD of 60 per 100,000 inhabitants.5 Based on these
numbers, we believe that half of the CD patients in Portugal
were included in this study, which may be considered a
representative sample.
To our knowledge this is the ﬁrst study assessing the
Montreal Classiﬁcation in a large cohort of patients with CD.
Most of the patients came from hospitals from north to south
Portugal, as well as the islands of Madeira and Azores,
covering all types of hospital care (primary to quaternary) in
an attempt to overcome a “referral-bias” which might have
existed if we only included patients from major referral
centers. Most of the investigators involved in the study were
senior gastroenterologists, and patients seen in private prac-
tice were also included. The Montreal Classiﬁcation individ-
ualized, for the ﬁrst time, a group for early onset of disease,
younger than 16 years old, allowing the investigation and
categorization of a pediatric group. According to previous
work, this group seems to be characterized by speciﬁc sero-
TABLE 4. Contingency for Age at Diagnosis, Location, and Behavior According to Treatment, Classiﬁed in 6 Disease Severity
Categories (Modiﬁcation of Silverstein et al4 Classiﬁcation) Silverstein Score
Silverstein Score
1 N (%) 2 N (%) 3 N (%) 4 N (%) 5 N (%) 6 N (%) Pa
Age onset
A1 7 (8) 4 (5) 27 (32) 14 (17) 18 (21) 14 (17)
A2 89 (12) 13 (2) 183 (24) 96 (13) 259 (35) 108 (14) 0.001
A3 41 (20) 5 (3) 38 (19) 24 (12) 80 (40) 14 (7)
Location
L1L14 66 (18) 5 (1) 55 (15) 26 (7) 194 (52) 31 (8)
L2L24 32 (15) 7 (3) 70 (32) 59 (27) 26 (12) 25 (11) 0.001
L3L34 36 (9) 8 (2) 120 (28) 49 (12) 135 (32) 76 (18)
Behavior
B1B1p 100 (30) 11 (3) 13 (37) 48 (15) 38 (11) 14 (4)
B2B2p 15 (7) 2 (9) 33 (15) 4 (2) 146 (68) 16 (7) 0.001
B3B3p 10 (3) 4 (1) 41 (14) 17 (6) 156 (52) 75 (25)
Score 1 was reserved for mild disease (without steroids, immunosuppressants, biologic treatment or surgery at any given year of disease), score 2 for moderate
disease (patients treated with corticosteroids requiring a dose of prednisolone above 10 mg/day or 2 or more steroid treatments within a period of 6 months),
score 3 for severe disease (patients treated with immunosuppressants without biologic treatment or surgery), score 4 for severe refractory disease (patients
treated with immunosuppressants and biologic treatment without surgery), score 5 for surgically treated disease (patients without immunosuppressants or
biologic treatment), and score 6 to severe refractory disease who score 6 to severe refractory disease who came to need surgery and also immunosuppressants
and biologic treatment. aPearson chi-square test.
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types and genotypes.1 In our population, A1 patients appear
to be a different CD group. They were more often steroid-
dependent and immunosuppressed and they had more EIMs.
This is in agreement with previous studies which report a
more severe phenotype with steroid resistance and a greater
need for immunosuppression.6 These ﬁndings further empha-
size the need for early steroid-sparing medications in pediat-
ric IBD. As opposed to what could be expected, we observed
a low frequency of patients with a family history (7%) of CD
in the pediatric group, thereby suggesting that genetic factors
are not as important in the early onset phenotype and sug-
gesting that pediatric IBD is still evolving, and points to
environmental factors contributing to its pathogenesis.
Patients with disease diagnosed after 40 years of age, in
agreement with a previous study,7 were less frequently ste-
roid-dependent, and consequently, immunosuppression and
biologic therapy was less often prescribed. However, in our
study group we did not ﬁnd a tendency for a decreased rate of
abdominal surgery, as reported before.8 With respect to dis-
ease location, the most important difﬁculty with the Vienna
Classiﬁcation arose with the inability of allowing upper GI
involvement to coexist with distal disease. The Working
Party of the 1998 Vienna World Congress of Gastroenterol-
ogy,9 reported that 7% of patients were reported as L4, but in
the presents series only 1% of our patients had exclusive
location in the upper digestive tract. This is similar to a
previous study from Freeman,10 who reported a low exclusive
involvement of the upper digestive tract (0.8%). Thus, the
majority of patients who have upper GI tract involvement
also have disease in other locations. In the present series,
3.3% of upper GI tract involvement was associated with ileal
location (L14), 1.5% was associated with colonic disease
(L24), and 0.4% with ileocolonic disease (L34). Overall, 5.2%
of patients included in this study had upper GI tract involve-
ment, although these numbers might change with the wider
utilization of wireless capsule endoscopy.
Also, in the Vienna Classiﬁcation perianal ﬁstulizing
disease was included in the penetrating behavior group, but
the Working Party felt that perianal disease requires separate
subclassiﬁcation.1 In our cohort, 38% of patients had non-
stricturing and nonpenetrating disease, while 26% were clas-
siﬁed as stricturing and 36% as penetrating. As 4% of patients
had perianal disease without any more abdominal penetrating
events, in the present series we may admit that 4% of patients
would be erroneously classiﬁed as penetrating disease ac-
cording to the Vienna Classiﬁcation.
CD location changes only minimally over time, as
opposed to the disease behavior changing from pure inﬂam-
matory to stricturing or ﬁstulizing disease, with almost 90%
of patients progressing to complicated behavior after 20 years
of disease.11,12 All these arguments favor the hypothesis that
if we become accustomed to categorizing CD according to
the Montreal Classiﬁcation, in terms of location and age of
onset, we may very well be able to predict which is the most
probable outcome in the coming years, namely, need for
steroids, immunosuppressants, and/or surgery. In this work to
put out changes in location and behavior in the ﬁrst years of
disease, we only included patients with more than 5 years of
disease. We observed that, in agreement with previous stud-
ies,13 ileal involvement was associated with the need for
surgical interventions, as opposed to ileocolonic and upper
digestive tract involvement, which were associated with im-
munosuppression. If we consider the severity index used
herein, the Silverstein et al4 modiﬁed categorization, which
basically reﬂects the step-up policy that most physicians still
use when treating CD, in ascending order sulfasalazine,
5-aminosalicylate, corticosteroids, immunosuppressants, and
surgery, we found that disease phenotype, location, and age
of disease onset were associated with different disease sever-
ity categories.
Finally, we would like to emphasize that in the present
series, 78% of our patients had been on steroids, at least once,
49% had taken immunosuppressants at some point of their
disease, and at least 48% submitted to surgery. Less than 10%
of CD patients persisted without steroids, immunosuppres-
sants, or abdominal surgery. These numbers are quite similar
to previous series published from North America or from
Denmark,14–19 and do not support the study by Wolters et al,2
where the authors concluded that southern CD had a milder
course as compared to patients from northern Europe. They
reported a phenotypic north-to-south gradient in CD, illus-
trated by higher surgery risks in some northern European
centers, whereas patients from southern Europe were more
likely to pass from severe disease to a milder state, and from
there back to the no-medication state. However, it is impor-
tant to recall that in the Wolters et al study2 there were only
13 Portuguese patients included. In a recent study from only
one hospital in Portugal (quaternary medical center of IBD in
the north), only 10% of patients maintained a long-term
remission free of steroids after their initial presentation.20
Thus, according to the present results, we believe that rates of
aggressive medical therapy and the need for surgical inter-
ventions are very similar to the ones observed and reported in
northern European countries.
In conclusion, we were able to clearly demonstrate that
there are prognostic differences in the subgroups of patients
allocated by the Montreal Classiﬁcation. Our study shows
that stratifying CD patients with respect to disease location as
well as age of disease onset may prove useful in predicting
the subsequent course in terms of steroids requirement, im-
munosuppression, and/or surgical interventions. Furthermore,
we also want to emphasize that this is probably the largest
study coming from a country in southern Europe. In contrast
to what had been reported previously, but similar to the series
from northern Europe, only a minority of patients will have
mild disease.
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